These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17636185)

  • 21. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
    Weiskopf RB
    Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
    Mariani G; Konkle BA; Ingerslev J
    Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom.
    Morris S; Ridley S; Munro V; Christensen MC
    Anaesthesia; 2007 Jan; 62(1):43-52. PubMed ID: 17156226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant factor VIIa and the surgical patient.
    Scarpelini S; Rizoli S
    Curr Opin Crit Care; 2006 Aug; 12(4):351-6. PubMed ID: 16810047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy.
    Bauzá G; Hirsch E; Burke P; Quillen K
    Transfusion; 2007 Apr; 47(4):749-51. PubMed ID: 17381636
    [No Abstract]   [Full Text] [Related]  

  • 26. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor.
    Laguna P; Klukowska A
    Haemophilia; 2005 Jan; 11(1):2-4. PubMed ID: 15660981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of recombinant factor VIIa for bleeding in paediatric practice.
    Millar CG; Stringer MD; Sugarman I; Richards M
    Haemophilia; 2005 Mar; 11(2):171-4. PubMed ID: 15810920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology and clinical use of recombinant activated factor seven in neurosciences.
    Hartmann M; Sucker C
    Neurocrit Care; 2007; 6(2):149-57. PubMed ID: 17522800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. rFVIIa (Novoseven): the new panacea?
    Ickx BE
    Acta Anaesthesiol Belg; 2003; 54(4):333-5. PubMed ID: 14719355
    [No Abstract]   [Full Text] [Related]  

  • 30. "Evaluation of off-label recombinant activated factor VII for multiple indications in children" by Reiter et al.
    de Miranda PA
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):247; author reply 247. PubMed ID: 18372280
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of recombinant factor VIIa (NovoSeven) for treatment of active or impending bleeding in brain injury: broadening the indications.
    Yusim Y; Perel A; Berkenstadt H; Attia M; Knoller N; Sidi A
    J Clin Anesth; 2006 Nov; 18(7):545-51. PubMed ID: 17126787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
    Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
    Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of recombinant activated factor VII in intractable bleeding during pediatric neurosurgical procedures.
    Uhrig L; Blanot S; Baugnon T; Orliaguet G; Carli PA; Meyer PG
    Pediatr Crit Care Med; 2007 Nov; 8(6):576-9. PubMed ID: 18062085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
    Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
    Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
    Ozelo MC; Villaça PR; De Almeida JO; Bueno TM; De Miranda PA; Hart WM; Karamalis M
    Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When all else fails to stop massive bleeding from trauma.
    Thompson AR
    J Thromb Haemost; 2005 Apr; 3(4):638-9. PubMed ID: 15842346
    [No Abstract]   [Full Text] [Related]  

  • 37. Administration of recombinant activated factor VII (NovoSeven) in three cases of uncontrolled bleeding caused by disseminated intravascular coagulopathy.
    Schmid S; Friesenecker B; Lorenz I; Innerhofer P; Koscielny J; Velik-Salchner C; Mutz N; Fries D
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):313-7. PubMed ID: 17636194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
    Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
    MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
    Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of recombinant factor VII to control bleeding in a patient supported by right ventricular assist device after heart transplantation.
    Kogan A; Berman M; Kassif Y; Raanani E; Stamler A; Ben Gal T; Stein M; Erez E; Vidne BA; Sahar G
    J Heart Lung Transplant; 2005 Mar; 24(3):347-9. PubMed ID: 15737765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.